Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $36.80 Average PT from Analysts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) has been given an average rating of “Buy” by the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among […]

Related Keywords

United States ,Canada ,America ,Stephenf Betz ,Ajay Madan ,Securities Exchange Commission ,Zacks Investment Research ,Crinetics Pharmaceuticals Inc ,Deutsche Bank ,America Corp ,Parametric Portfolio Associates ,Nasdaq ,Analyst Recommendations For Crinetics Pharmaceuticals ,Crinetics Pharmaceuticals Get Rating ,Group Plc ,Royal Bank ,Crinetics Pharmaceuticals ,Get Rating ,Exchange Commission ,General Group Plc ,Portfolio Associates ,Nasdaq Crnx ,Crnx ,Medical ,Ratings ,Consensus ,